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Purpose of the study
Elderly patients (≥50 years) are increasing in the HIV pop-
ulation; HAART-related prolonged survival and late diag-
nosis of new HIV infections are possible reasons of this
findings. It is debated whether older patients have a differ-
ent response to HAART. The aim of this retrospective
study was to evaluate efficacy of HAART and clinical out-
come in a group of patients ≥50 year in comparison to a
control group (<50 years-old).
Methods
All naïve patients starting HAART since November 1996
in two different Infectious Diseases units in Catania (Sic-
ily) were included. The following parameters were evalu-
ated: epidemiological (sex, age, risk factors, year of
HAART beginning), viro-immunological (CD4 cell count,
HIV-RNA viral load), and clinical (CDC, first treatment,
number and causes of therapeutic switch, new AIDS dis-
eases and death). The follow-up was performed until the
last available visit.
Summary of results
We enrolled 276 HIV-1-infected patients; 215 (78%)
male, median age 38 years; 122 (44%) heterosexuals, 103
(38%) homo-bisexuals, 43 (16%) drug addicts; 139
(50.4%) CDC A, 31 (11.2%) CDC B, 106 (38.4%) CDC
C; median CD4 cell count was 155 (IQ range 48–301),
median HIV-RNA viral load 5.0 log10 (IQ range 4.3–5.4).
Fifty-one patients (18.5%) were ≥50 years old, 82.4%
male, most of them infected by sexual intercourse (p =
0.002). At baseline, elderly patients were more frequently
symptomatic (p = 0.002) with a trend to lower CD4 cell
count (98 vs. 169 cells/μl); no differences were seen on
HIV-RNA copies/ml. Twelve months after beginning of
HAART, median absolute increase (146 vs. 165 cells/μl) of
the CD4 cell count and percentage of patients with HIV-
RNA <400 copies/ml (87.2% vs. 85.7%) were comparable
in elderly and younger patients, respectively 82.1% and
82.8% achieved an immuno-virological response
(defined as VL <400 copies/ml and more than 100 CD4
cells/μl increase). At last, 65% and 16% of elderly patients
achieved, respectively, more than 200 and more than 500
CD4 cell/μl with no significant difference with younger
patients. Discontinuation of HAART (any causes) was less
frequent in older subjects (p = 0.04). After a median fol-
low-up of 68 months, the percentage of deaths was 15.7%
and 5.8% (p = 0.034) in the elderly and younger group,
respectively.
Conclusion
In our experience, elderly and younger naive patients on
HAART have similar immunological and virological
response while hard clinical end-points tend to be more
frequent in older subjects. Prospective studies are neces-
sary to further investigate our findings.
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